Valerio Therapeutics S.A
Paris, Ile-de-France, France · Biotechnology, Health Care, Therapeutics
Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) is a clinical-stage biotechnology company leading the way in the development of innovative DNA Decoy therapeutics. It is committed to bringing innovative therapeutics to patients and focusing on developing treatments for severe and life-threatening diseases including but not limited to autoimmune and inflammatory diseases as well as cancers.
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- Paris, Ile-de-France, France
- Employees
- 62
- Industries
- Biotechnology, Health Care, Therapeutics
- Status
- Private
- Website
- valeriotx.com
- Company page
Recent activity at Valerio Therapeutics S.A
About Valerio Therapeutics S.A: questions and answers
What does Valerio Therapeutics S.A do?
Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) is a clinical-stage biotechnology company leading the way in the development of innovative DNA Decoy therapeutics. It is committed to bringing innovative therapeutics to patients and focusing on developing treatments for severe and life-threatening diseases including but not limited to autoimmune and inflammatory diseases as well as cancers.
Where is Valerio Therapeutics S.A headquartered?
Valerio Therapeutics S.A is headquartered in Paris, Ile-de-France, France.
How many employees does Valerio Therapeutics S.A have?
Valerio Therapeutics S.A has about 62 employees.
What is the latest news on Valerio Therapeutics S.A?
On Jul 01, 2026, Valerio Therapeutics to acquire Etherna Immunotherapies
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy